HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...
HER3 is expressed in more than 80% of EGFR-mutant ... AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive ...
HER3 is expressed in more than 80% of EGFR-mutant ... Meanwhile, Daiichi Sankyo and AZ – its partner for approved HER2-targeting ADC Enhertu (trastuzumab deruxtecan) and investigational TROP2 ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback